News

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...
Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...
Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...